Dublin, Sept. 10, 2020 (GLOBE NEWSWIRE) -- The "Drug Repurposing Service Providers Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current market landscape and future opportunities for players offering services for repurposing/repositioning/reprofiling of drug candidates. The study also includes an in-depth analysis, highlighting the capabilities of various service providers engaged in this domain.

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the drug repurposing service providers market. Based on various important parameters, such as projected rise in the overall pharmaceutical R&D expenditure, drug discovery costs, and outsourcing profile, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of repurposing approach (disease centric, target-centric and drug-centric), [B] therapeutic area (same therapeutic area and different therapeutic area), [C] type of drug molecule (biologic and small molecule), and [D] key geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth. In addition, the report discusses the impact of the recent COVID-19 pandemic on the global drug repurposing service providers market, along with providing details related to the future market opportunity for players engaged in this domain.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players offering drug repurposing services?
  • What kind of initiatives have been undertaken by big pharma players related to drug repurposing?
  • What kind of partnership models are most commonly adopted by stakeholders in this industry?
  • What is the role of non-profit organizations and academic players in this domain?
  • What are the potential cost benefits of drug repurposing, compared to the traditional drug development process?
  • What factors are likely to influence the evolution of this upcoming market?
  • How has the recent COVID-19 pandemic likely impacted the demand for drug repurposing?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE

5. ROLE OF NON-PROFIT/ACADEMIC ORGANIZATIONS

6. COMPANY PROFILES

7. PARTNERSHIPS

8. BIG PHARMA INITIATIVES

9. CASE STUDY: DISCONTINUED DRUG DEVELOPMENT PROGRAMS

10. COST SAVING ANALYSIS

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS

12. COVID-19 IMPACT ON DRUG REPURPOSING SERVICE PROVIDERS MARKET

13. RECENT ADVANCEMENTS AND TRENDS IN OUTSOURCING OF DRUG REPURPOSING

14. INTERVIEW TRANSCRIPTS

15. APPENDIX 1: LIST OF POTENTIAL DRUG-INDICATION CANDIDATES FOR DRUG REPURPOSING

16. APPENDIX 2: TABULATED DATA

Companies Mentioned

  • 3BIGS
  • IIT Kharagpur
  • AbbVie
  • Abiomics Europe
  • Actto Pharma
  • AI VIVO
  • Ampel Biosolutions
  • Anaxomics
  • Anticancer Fund
  • Apodd
  • Ariel University
  • Astellas Pharma
  • AstraZeneca
  • Auxilis Pharma
  • Avivia
  • Bayer
  • BayPoint Biosystems
  • BenevolentAI
  • Bill & Melinda Gates
  • Biovista
  • Bioxcel
  • BioXplor
  • Boehringer Ingelheim
  • Bright Focus Foundation
  • Cardiomedex
  • Carnegie Mellon University
  • ChemBio Discovery Solutions
  • Chordoma Foundation
  • Eli Lilly
  • Empiric Logic
  • espeRare
  • Euretos
  • Eurofins
  • Evotec
  • Excelra
  • FindaCure
  • Fios Genomics
  • Fraxa
  • Galactica Biotech
  • Garvan Institute of Medical Research
  • Genome Biologics
  • Gilead Sciences
  • GlobalCures
  • Green Pharma
  • GSK
  • GVK BIO
  • Harrington Discovery Institute
  • Hartwig Medical Foundation
  • Healx
  • Helomics
  • Hybrigenics Services
  • IBM
  • Innoplexus
  • Innovate UK
  • Insiliance
  • Intomics
  • Iris Pharma
  • Jeeva Informatics
  • Johns Hopkins University
  • Keio University
  • Lantern Pharma
  • LEA
  • Linguamatics
  • McGill University
  • Plebiotic
  • Protavio
  • Purdue University
  • Purposeful
  • Qrativ
  • RASA Life Science Informatics
  • Recursion Pharmaceuticals
  • Rediscovery Life Sciences
  • Reinvent Pharma
  • Robert Wood Johnson Foundation
  • Roche
  • Safan Bioinformatics
  • Sanofi
  • Selleck Chemical
  • Shake it up
  • Signia Therapuetics
  • Sistemic
  • Smart Pharma
  • SmartLigs
  • Socium
  • SOM Biotech
  • Stagen
  • Standigm
  • Syngene
  • SystaMedic
  • Therametrics
  • Therasis
  • Tovem
  • TranScientae
  • Transmed

For more information about this report visit https://www.researchandmarkets.com/r/533rvn

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900